2021
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era
Schiffer M, Zhao J, Johnson A, Lee J, Bewersdorf JP, Zeidan AM. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. Expert Review Of Anticancer Therapy 2021, 21: 989-1002. PMID: 33853476, DOI: 10.1080/14737140.2021.1918002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myelomonocytic leukemiaAcute myeloid leukemiaMyelodysplastic syndromeMyeloid leukemiaMyelomonocytic leukemiaHypomethylating agentAllogeneic hematopoietic cell transplantPost-transplant maintenance therapyAcute myeloid leukemia (AML) treatmentHematopoietic cell transplantHigh-risk MDSMyeloid leukemia treatmentPotential combination therapyCC-486Induction chemotherapyOral azacitidineTherapy eraMaintenance therapyOral agentsAdult patientsCell transplantClinical benefitMaintenance treatmentCombination therapyPredictive biomarkers
2019
Healthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAML